Kiniksa Pharmaceuticals International, plc

Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.

KNSA | US

Overview

Corporate Details

ISIN(s):: BMG5269C1010
LEI:
Country:: United States of America
Address:: 23 OLD BOND STREET, FLOOR 3, LONDON
Website:: https://www.kiniksa.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for debilitating diseases with significant unmet medical needs. The company's portfolio is centered on innovative, immune-modulating assets. Its pipeline includes investigational therapies for conditions such as recurrent pericarditis, addressing diverse patient needs through novel treatments. Kiniksa operates with a patient-centric mission, aiming to deliver therapies to individuals with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kiniksa Pharmaceuticals International, plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kiniksa Pharmaceuticals International, plc

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kiniksa Pharmaceuticals International, plc via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Editas Medicine, Inc. Developing CRISPR-based genomic medicines to treat serious and rare genetic diseases.	United States of America	EDIT
Eevia Health Plc Manufactures validated polyphenol extracts from Arctic plants for the supplement & food industries.	Finland	EEVIA
Egetis Therapeutics Develops and commercializes drugs for serious rare diseases with unmet medical needs.	Sweden	EGTX
EIKEN CHEMICAL CO.,LTD. Manufacturer of clinical diagnostics, specializing in FIT systems for cancer and microbiological tests.	Japan	4549
Eisai Co., Ltd. A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.	Japan	4523
Elanco Animal Health Inc Develops medicines, vaccines, and services to treat and prevent disease in pets and farm animals.	United States of America	ELAN
Eledon Pharmaceuticals, Inc. Develops immunomodulatory therapies to prevent organ rejection in transplant patients.	United States of America	ELDN
Elicera Therapeutics AB Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.	Sweden	ELIC
ELI LILLY & Co Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.	United States of America	LLY
Ellen AB Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.	Sweden	ELN